{"title":"血浆淀粉样蛋白-β前体蛋白669-711/淀粉样蛋白-β1-42比值与阿尔茨海默病的认知相关","authors":"Moeko Noguchi-Shinohara, Yasuhiro Sakashita, Hiroto Nakano, Daiki Muramatsu, Sadao Hikishima, Junji Komatsu, Hidetomo Murakami, Yukiko Mori, Kenjiro Ono","doi":"10.1016/j.tjpad.2024.100003","DOIUrl":null,"url":null,"abstract":"<p><p>Plasma amyloid-β (Aβ) markers are significant predictors of Aβ pathology. However, their prognostic value for cognition in patients with Alzheimer's disease (AD) is unknown. We compared plasma amyloid-β precursor protein (APP)<sub>669-711</sub> and Aβ<sub>1-42</sub> levels between cognitively unimpaired participants (CU) and those with MCI due to AD and AD dementia. The CU group was divided into CU+ or CU- groups according to presence of Aβ pathology. All patients with AD exhibited Aβ pathology. The plasma APP<sub>669-711</sub>/Aβ<sub>1-42</sub> ratio was significantly elevated in patients with CU+, MCI+, and AD+ compared with those with CU-. Furthermore, the plasma APP<sub>669-711</sub>/Aβ<sub>1-42</sub> ratio was significantly correlated with the MMSE score (rs = -0.544, p < 0.001). Analysis of the Aβ+ group revealed that the significant relationship between MMSE score and plasma APP<sub>669-711</sub>/Aβ<sub>1-42</sub> ratio remained unchanged (rs = -0.244, p = 0.027). Therefore, we conclude that the plasma APP<sub>669-711</sub>/Aβ<sub>1-42</sub> ratio is associated with cognition in patients with AD.</p>","PeriodicalId":22711,"journal":{"name":"The Journal of Prevention of Alzheimer's Disease","volume":"12 1","pages":"100003"},"PeriodicalIF":4.3000,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Plasma amyloid-β precursor protein <sub>669-711</sub>/amyloid-β<sub>1-42</sub> ratio is associated with cognition in Alzheimer's disease.\",\"authors\":\"Moeko Noguchi-Shinohara, Yasuhiro Sakashita, Hiroto Nakano, Daiki Muramatsu, Sadao Hikishima, Junji Komatsu, Hidetomo Murakami, Yukiko Mori, Kenjiro Ono\",\"doi\":\"10.1016/j.tjpad.2024.100003\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Plasma amyloid-β (Aβ) markers are significant predictors of Aβ pathology. However, their prognostic value for cognition in patients with Alzheimer's disease (AD) is unknown. We compared plasma amyloid-β precursor protein (APP)<sub>669-711</sub> and Aβ<sub>1-42</sub> levels between cognitively unimpaired participants (CU) and those with MCI due to AD and AD dementia. The CU group was divided into CU+ or CU- groups according to presence of Aβ pathology. All patients with AD exhibited Aβ pathology. The plasma APP<sub>669-711</sub>/Aβ<sub>1-42</sub> ratio was significantly elevated in patients with CU+, MCI+, and AD+ compared with those with CU-. Furthermore, the plasma APP<sub>669-711</sub>/Aβ<sub>1-42</sub> ratio was significantly correlated with the MMSE score (rs = -0.544, p < 0.001). Analysis of the Aβ+ group revealed that the significant relationship between MMSE score and plasma APP<sub>669-711</sub>/Aβ<sub>1-42</sub> ratio remained unchanged (rs = -0.244, p = 0.027). Therefore, we conclude that the plasma APP<sub>669-711</sub>/Aβ<sub>1-42</sub> ratio is associated with cognition in patients with AD.</p>\",\"PeriodicalId\":22711,\"journal\":{\"name\":\"The Journal of Prevention of Alzheimer's Disease\",\"volume\":\"12 1\",\"pages\":\"100003\"},\"PeriodicalIF\":4.3000,\"publicationDate\":\"2025-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"The Journal of Prevention of Alzheimer's Disease\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1016/j.tjpad.2024.100003\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"BUSINESS\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"The Journal of Prevention of Alzheimer's Disease","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1016/j.tjpad.2024.100003","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"BUSINESS","Score":null,"Total":0}
引用次数: 0
摘要
血浆淀粉样蛋白-β (Aβ)标志物是Aβ病理的重要预测因子。然而，它们对阿尔茨海默病（AD）患者认知的预后价值尚不清楚。我们比较了认知未受损参与者（CU）和因AD和AD痴呆而患有MCI的参与者（CU）血浆淀粉样蛋白-β前体蛋白（APP）669-711和a -β 1-42的水平。根据Aβ的病理表现将CU组分为CU+组和CU-组。所有AD患者均表现为Aβ病理。与CU-患者相比，CU+、MCI+和AD+患者血浆APP669-711/ a - β1-42比值显著升高。血浆APP669-711/ a - β1-42比值与MMSE评分显著相关（rs = -0.544, p < 0.001）。Aβ+组MMSE评分与血浆APP669-711/Aβ1-42比值无显著相关性（rs = -0.244, p = 0.027）。因此，我们认为血浆APP669-711/ a - β1-42比值与AD患者认知相关。
Plasma amyloid-β precursor protein 669-711/amyloid-β1-42 ratio is associated with cognition in Alzheimer's disease.
Plasma amyloid-β (Aβ) markers are significant predictors of Aβ pathology. However, their prognostic value for cognition in patients with Alzheimer's disease (AD) is unknown. We compared plasma amyloid-β precursor protein (APP)669-711 and Aβ1-42 levels between cognitively unimpaired participants (CU) and those with MCI due to AD and AD dementia. The CU group was divided into CU+ or CU- groups according to presence of Aβ pathology. All patients with AD exhibited Aβ pathology. The plasma APP669-711/Aβ1-42 ratio was significantly elevated in patients with CU+, MCI+, and AD+ compared with those with CU-. Furthermore, the plasma APP669-711/Aβ1-42 ratio was significantly correlated with the MMSE score (rs = -0.544, p < 0.001). Analysis of the Aβ+ group revealed that the significant relationship between MMSE score and plasma APP669-711/Aβ1-42 ratio remained unchanged (rs = -0.244, p = 0.027). Therefore, we conclude that the plasma APP669-711/Aβ1-42 ratio is associated with cognition in patients with AD.
期刊介绍：
The JPAD Journal of Prevention of Alzheimer’Disease will publish reviews, original research articles and short reports to improve our knowledge in the field of Alzheimer prevention including: neurosciences, biomarkers, imaging, epidemiology, public health, physical cognitive exercise, nutrition, risk and protective factors, drug development, trials design, and heath economic outcomes.JPAD will publish also the meeting abstracts from Clinical Trial on Alzheimer Disease (CTAD) and will be distributed both in paper and online version worldwide.We hope that JPAD with your contribution will play a role in the development of Alzheimer prevention.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
